We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Cytosorbents Corporation (CTSO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.9048 |
| Open | 0.8900 |
| Bid | 0.8489 x 100 |
| Ask | 0.9316 x 100 |
| Day's Range | 0.8650 - 0.9400 |
| 52 Week Range | 0.8400 - 4.2900 |
| Volume | |
| Avg. Volume | 132,483 |
| Market Cap | 47.344M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6400 |
| Earnings Date | Apr 30, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.70 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CTSO
Related Research
- Cytosorbents CorporationAnalyst Report: Illumina IncIllumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic analysis. The company's products and services are sold to genomic research centers, academic institutions, government and commercial laboratories, and hospitals, as well as to pharmaceutical, biotech, agrigenomics, and consumer genomics businesses. The company's portfolio of products and services is designed to accelerate and simplify genetic analysis. Illumina also invests in startup companies that are pursuing promising genomic-related opportunities. It has roughly 10,590 full-time employees, including 9,250 employees at Core Illumina and 1,340 employees at GRAIL. ILMN shares are included in the S&P 500 index.RatingFair ValueEconomic Moat3 days agoArgus Research
- Zacks Small Cap Research
CTSO: CytoSorbents Expects Significant Gross Margin Expansion in 2024.
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT For the full year 2023, total revenues increased approximately 5.0% to $36.3 million. Total product sales were $31.1 million, an increase of 6.0% from 2022. 2022 sales benefitted from $0.7 million in other non-CytoSorb sales and $0.3 million in COVID-19 related sales that did not recur in 2023. Core (non-Covid-19 related) CytoSorb
Simply Wall St.These Analysts Think Cytosorbents Corporation's (NASDAQ:CTSO) Sales Are Under Threat
The analysts covering Cytosorbents Corporation ( NASDAQ:CTSO ) delivered a dose of negativity to shareholders today, by...
Simply Wall St.Cytosorbents Full Year 2023 Earnings: Misses Expectations
Cytosorbents ( NASDAQ:CTSO ) Full Year 2023 Results Key Financial Results Revenue: US$36.3m (up 4.8% from FY 2022). Net...
Insider MonkeyCytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript March 14, 2024 Cytosorbents Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the CytoSorbents’ Fourth Quarter and Full-Year 2023 Financial and Operating Results Conference Call. At […]
- Thomson Reuters StreetEvents
Q4 2023 Cytosorbents Corp Earnings Call
Q4 2023 Cytosorbents Corp Earnings Call
GlobeNewswireCytoSorbents Reports Fourth Quarter and Full Year 2023 Results
STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration (FDA) and Health Canada this year CytoSorb core sales increased approximately 10% year-over-year 2023 Product gross margins increased to 72% Cumulative CytoSorb treatments surpassed 228,000 PRINCETON, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Co
- GlobeNewswire
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on Thursday, March 14th, 2024 at 4:30PM EDT. CytoSorbents’ management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q4 2023 and fiscal year ending December 31
- Simply Wall St.
Cytosorbents (NASDAQ:CTSO) investors are sitting on a loss of 90% if they invested three years ago
As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses...
- GlobeNewswire
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place, in Boston, MA on Wednesday, March 6th, 2024. Company management will also meet in-person with investors in 1x1 meetings
- Zacks Small Cap Research
CTSO: CytoSorbents reports update on data results from important U.S. and Canadian STAR-T pivotal trial.
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On December 28, 2023, CytoSorbents (NASDAQ:CTSO) announced an update on the initial data analysis of the primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board (“DSMB”) analysis for the important U.S. and Canadian STAR-T (Safe and Timely Antithrombotic Removal of Ticagrelor)
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| CTMX CytomX Therapeutics, Inc. | |||
| AXGN AxoGen, Inc. | |||
| APYX Apyx Medical Corporation | |||
| EIGR Eiger BioPharmaceuticals, Inc. | |||
| CDXC ChromaDex Corporation |
Similar to CTSO
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| AEMD Aethlon Medical, Inc. | |||
| DHAI DIH Holding US, Inc. | |||
| TIVC Tivic Health Systems, Inc. | |||
| BVS Bioventus Inc. | |||
| VIVE Viveve Medical, Inc. |
Analyst Price Targets (5)
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 3/15/2024 | |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 12/29/2023 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/2/2023 | |
| Reiterates | HC Wainwright & Co.: to Buy | 5/3/2023 | |
| Reiterates | HC Wainwright & Co.: to Buy | 3/10/2023 | |
| Maintains | HC Wainwright & Co.: to Buy | 11/4/2022 |
Company Profile
305 College Road East
Princeton, NJ 08540
United States
732 329 8885
https://www.cytosorbents.com
Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 186
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
